Johnson & Johnson to Post FY2022 Earnings of $11.85 Per Share, Leerink Swann Forecasts (JNJ)
Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Leerink Swann issued their FY2022 EPS estimates for shares of Johnson & Johnson in a research report issued to clients and investors on Thursday, May 17th. Leerink Swann analyst D. Antalffy expects that the company will post earnings of $11.85 per share for the year. Leerink Swann has a “Outperform” rating and a $160.00 price target on the stock.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. The firm had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The business’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.83 EPS.
Johnson & Johnson opened at $123.85 on Friday, according to Marketbeat. The firm has a market cap of $336.30 billion, a PE ratio of 16.97, a PEG ratio of 1.92 and a beta of 0.74. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a one year low of $125.00 and a one year high of $125.73.
A number of institutional investors have recently bought and sold shares of JNJ. BlackRock Inc. lifted its stake in Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after purchasing an additional 7,853,141 shares during the last quarter. Boston Partners lifted its stake in Johnson & Johnson by 68.7% in the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after purchasing an additional 5,207,124 shares during the last quarter. Stifel Financial Corp increased its position in shares of Johnson & Johnson by 6,715.9% in the third quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after acquiring an additional 2,534,918 shares during the period. Mackenzie Financial Corp increased its position in shares of Johnson & Johnson by 55.1% in the fourth quarter. Mackenzie Financial Corp now owns 4,243,594 shares of the company’s stock valued at $592,915,000 after acquiring an additional 1,507,278 shares during the period. Finally, Flossbach Von Storch AG increased its position in shares of Johnson & Johnson by 100.1% in the first quarter. Flossbach Von Storch AG now owns 2,318,450 shares of the company’s stock valued at $297,109,000 after acquiring an additional 1,159,690 shares during the period. 67.40% of the stock is owned by institutional investors and hedge funds.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th will be paid a $0.90 dividend. The ex-dividend date of this dividend is Friday, May 25th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a yield of 2.91%. Johnson & Johnson’s payout ratio is currently 46.03%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.